ProKidney Corp. (PROK )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol PROK
- Company ProKidney Corp.
- Price $0.83
- Changes Percentage -8.47
- Change -0.0771
- Day Low $0.81
- Day High $0.92
- Year High $4.44
- Year Low $0.46
- Market Cap $248,822,278
- Price Avg 50 EMA (D) $1.03
- Price Avg 200 EMA (D) $1.73
- Exchange NASDAQ
- Volume 106,968
- Average Volume 729,757
- Open $0.92
- Previous Close $0.91
- EPS -0.75
- PE -1.13
- Earnings Announcement 2025-05-09 12:00:00
- Shares Outstanding $292,697,657
Company brief: PROKIDNEY CORP. (PROK )
- Healthcare
- Biotechnology
- Dr. Bruce Culleton M.D.
- https://www.prokidney.com
- US
- N/A
- 06-30-2021
- KYG7S53R1049
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease; and Phase I clinical trial for patients with congenital anomalies of the kidney and urinary tract. The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.